Two Doses of Polatuzumab Vedotin in Patients With Relapsed/Refractory Follicular Lymphoma

Catherine M. Diefenbach, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses the efficacy of two doses of polatuzumab vedotin (POV) in patients with relapsed/refractory (RR) follicular lymphoma (FL).